Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non Operating Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non Operating Income for 4 consecutive years, with -$15.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 1.24% to -$15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$61.3 million, a 7.74% decrease, with the full-year FY2025 number at -$61.3 million, down 7.74% from a year prior.
  • Non Operating Income was -$15.2 million for Q4 2025 at Phathom Pharmaceuticals, up from -$30.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $16.8 million in Q3 2023 to a low of -$34.1 million in Q4 2023.
  • A 4-year average of -$9.5 million and a median of -$10.7 million in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 153072.73% in 2023, then crashed 471633.33% in 2024.
  • Phathom Pharmaceuticals' Non Operating Income stood at -$8.4 million in 2022, then tumbled by 305.78% to -$34.1 million in 2023, then skyrocketed by 55.92% to -$15.0 million in 2024, then decreased by 1.24% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Non Operating Income are -$15.2 million (Q4 2025), -$30.1 million (Q3 2025), and -$15.9 million (Q2 2025).